Aclaris Therapeutics (ACRS) EBITDA (2014 - 2026)

Aclaris Therapeutics' EBITDA history runs 13 years deep, the most recent figure standing at -$22.2 million for Q1 2026.

• On a quarterly basis, EBITDA fell 22.72% year-over-year to -$22.2 million in Q1 2026; TTM through Mar 2026 was -$80.5 million, a 42.95% increase from a year earlier, with the FY2025 full-year figure at -$76.4 million, up 46.19% from the prior year.
• EBITDA rose to -$22.2 million in Q1 2026 per ACRS's latest filing, from -$22.7 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.0 million in Q4 2023 and bottomed at -$99.7 million in Q4 2024.
• The 5-year median for EBITDA is -$20.9 million (2022), against an average of -$25.2 million.
• Across the five-year window, EBITDA surged 86.08% in 2023 and sank 2362.94% in 2024, its largest moves.
• Year by year, EBITDA stood at -$29.1 million in 2022, then jumped by 86.08% to -$4.0 million in 2023, then sank by 2362.94% to -$99.7 million in 2024, then soared by 77.19% to -$22.7 million in 2025, then climbed by 2.38% to -$22.2 million in 2026.
• Per Business Quant, the three latest ACRS EBITDA figures stand at -$22.2 million (Q1 2026), -$22.7 million (Q4 2025), and -$17.1 million (Q3 2025).